Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
- PMID: 15383478
- DOI: 10.1378/chest.126.3_suppl.338S
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Abstract
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following. We recommend against the use of aspirin alone as thromboprophylaxis for any patient group (Grade 1A). For moderate-risk general surgery patients, we recommend prophylaxis with low-dose unfractionated heparin (LDUH) (5,000 U bid) or low-molecular-weight heparin (LMWH) [< or = 3,400 U once daily] (both Grade 1A). For higher risk general surgery patients, we recommend thromboprophylaxis with LDUH (5,000 U tid) or LMWH (> 3,400 U daily) [both Grade 1A]. For high-risk general surgery patients with multiple risk factors, we recommend combining pharmacologic methods (LDUH three times daily or LMWH, > 3,400 U daily) with the use of graduated compression stockings and/or intermittent pneumatic compression devices (Grade 1C+). We recommend that thromboprophylaxis be used in all patients undergoing major gynecologic surgery (Grade 1A) or major, open urologic procedures, and we recommend prophylaxis with LDUH two times or three times daily (Grade 1A). For patients undergoing elective total hip or knee arthroplasty, we recommend one of the following three anticoagulant agents: LMWH, fondaparinux, or adjusted-dose vitamin K antagonist (VKA) [international normalized ratio (INR) target, 2.5; range, 2.0 to 3.0] (all Grade 1A). For patients undergoing hip fracture surgery (HFS), we recommend the routine use of fondaparinux (Grade 1A), LMWH (Grade 1C+), VKA (target INR, 2.5; range, 2.0 to 3.0) [Grade 2B], or LDUH (Grade 1B). We recommend that patients undergoing hip or knee arthroplasty, or HFS receive thromboprophylaxis for at least 10 days (Grade 1A). We recommend that all trauma patients with at least one risk factor for VTE receive thromboprophylaxis (Grade 1A). In acutely ill medical patients who have been admitted to the hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, we recommend prophylaxis with LDUH (Grade 1A) or LMWH (Grade 1A). We recommend, on admission to the intensive care unit, all patients be assessed for their risk of VTE. Accordingly, most patients should receive thromboprophylaxis (Grade 1A).
Comment in
-
Risk vs benefits for thromboembolic disease after total joint surgery.Chest. 2005 Jun;127(6):2297-8. doi: 10.1378/chest.127.6.2297-a. Chest. 2005. PMID: 15947368 No abstract available.
Similar articles
-
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656. Chest. 2008. PMID: 18574271
-
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):401S-428S. doi: 10.1378/chest.126.3_suppl.401S. Chest. 2004. PMID: 15383479 Review.
-
Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):645S-687S. doi: 10.1378/chest.126.3_suppl.645S. Chest. 2004. PMID: 15383489 Review.
-
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):627S-644S. doi: 10.1378/chest.126.3_suppl.627S. Chest. 2004. PMID: 15383488 Review.
-
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658. Chest. 2008. PMID: 18574272
Cited by
-
Learning to predict post-hospitalization VTE risk from EHR data.AMIA Annu Symp Proc. 2012;2012:436-45. Epub 2012 Nov 3. AMIA Annu Symp Proc. 2012. PMID: 23304314 Free PMC article.
-
Thromboembolic disease in cancer patients.Support Care Cancer. 2013 May;21(5):1481-6. doi: 10.1007/s00520-013-1742-6. Epub 2013 Feb 21. Support Care Cancer. 2013. PMID: 23430009 Review.
-
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.Am Health Drug Benefits. 2016 Jun;9(4):221-32. Am Health Drug Benefits. 2016. PMID: 27688834 Free PMC article.
-
Risk of Thromboembolism Following Body-Contouring Surgery After Massive Weight Loss.Eplasty. 2015 May 22;15:e17. eCollection 2015. Eplasty. 2015. PMID: 26171089 Free PMC article.
-
Modeling current practices in critical care comparative effectiveness research.Crit Care Resusc. 2023 Oct 19;24(2):150-162. doi: 10.51893/2022.2.OA5. eCollection 2022 Jun 6. Crit Care Resusc. 2023. PMID: 38045594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical